Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction ...
Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...
Learn more about the car you're interested in before you buy. Not quite sure where to start? Explore models that fit your needs. See all of the winners and nominees. Winner Nominee Nominee Nominee ...